Form 4: REGENXBIO Director Daniel Tasse Acquires Shares and Stock Options

Director Daniel Tasse acquired shares and stock options in REGENXBIO Inc. on May 31, 2024.

Summary

• On May 31, 2024, Daniel Tasse, a director of REGENXBIO Inc., acquired 4,790 shares of common stock underlying a time-based restricted stock unit award (RSU) at a price of $0.00.
• 100% of the shares subject to this RSU will vest on May 1, 2025, contingent upon continuous service to the Issuer.
• Tasse also acquired 24,454 stock options with an exercise price of $14.35.
• These options will vest in 12 equal monthly installments starting May 31, 2024, also subject to continuous service to the Issuer.
• Following these transactions, Tasse directly owns 11,286 shares of common stock and 24,454 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options by a director can be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future performance.
• The vesting schedules tied to continuous service align the director's interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules of the acquired securities suggest a long-term commitment from the director.

Industry Context

This is a routine disclosure of insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry.
• Vesting schedules tied to continuous service are standard practice to incentivize long-term commitment and align interests with shareholders.
• Comparable companies such as BioMarin Pharmaceutical, Sarepta Therapeutics, and Vertex Pharmaceuticals also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.
• Employees may view the vesting schedules as an incentive for long-term commitment.

Key Dates